The FDA requested additional clinical data from Unicycive Therapeutics.
3 reports, 2 independent
Updated Sep 22
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA requested additional clinical data from Unicycive Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Lawsuit alleges misleading statements by Unicycive regarding FDA scrutiny.1 source
FDA requested more clinical data from Unicycive Therapeutics.1 source
Keep exploring
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.